Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
Edited by Patrina Caldwell (email@example.com)
Conflict of interest: Oluwole Oni, Basil Elnazir, Taha Hassan and Peter Greally have nothing to declare. Dr Bosco Paes has received funding for investigator-initiated research projects from Abbott Laboratories and has been compensated as advisor and/or lecturer for Abbott and MedImmune.
Dr Basil Elnazir, Department of Paediatric Respiratory Medicine, National Children's Hospital, Tallaght, Dublin 24, Ireland. Fax: +35314142997; email: firstname.lastname@example.org